Title:
IMIDAZOPYRIDINE COMPOUND AS IRAK4 DEGRADATION AGENT AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/067845
Kind Code:
A1
Abstract:
An imidazopyridine compound represented by formula (I) as an IRAK4 degradation agent, a tautomer thereof, a stereoisomer thereof, a hydrate thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compound can be used for treating an IRAK4-related disease and holds great promise as a medicament.
Inventors:
ZHANG XUEJUN (CN)
ZANG YANG (CN)
YANG HUI (CN)
LI JINPING (CN)
SUN ZHENGJUN (CN)
ZHOU YUAN (CN)
LIU LIFEI (CN)
JIANG HUA (CN)
QIAN LINA (CN)
LI LIE (CN)
YANG JUN (CN)
ZANG YANG (CN)
YANG HUI (CN)
LI JINPING (CN)
SUN ZHENGJUN (CN)
ZHOU YUAN (CN)
LIU LIFEI (CN)
JIANG HUA (CN)
QIAN LINA (CN)
LI LIE (CN)
YANG JUN (CN)
Application Number:
PCT/CN2023/122818
Publication Date:
April 04, 2024
Filing Date:
September 28, 2023
Export Citation:
Assignee:
WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY (CN)
International Classes:
C07D471/04; A61K31/4188; A61K31/437; A61K31/454; A61K47/55; A61P9/00; A61P29/00; A61P35/00; A61P37/00; C07D401/14; C07D519/00
Domestic Patent References:
| WO2019099926A1 | 2019-05-23 | |||
| WO2020035020A1 | 2020-02-20 | |||
| WO2020150626A1 | 2020-07-23 | |||
| WO2022088551A1 | 2022-05-05 | |||
| WO2022147465A1 | 2022-07-07 | |||
| WO2023283372A1 | 2023-01-12 |
Foreign References:
| CN114502158A | 2022-05-13 |
Attorney, Agent or Firm:
SHANGHAI BESINGIP INTELLECTUAL PROPERTY AGENCY CO., LTD (CN)
Download PDF: